Prognosis of primary aldosteronism in japan: Results from a nationwide epidemiological study

Endocrine Journal

Volumn 61, Issue 1, 2014, Pages 35-40

  Miyake, Yoshihiro ^a   Tanaka, Keiko ^a   Nishikawa, Tetsuo ^b   Naruse, Mitsuhide ^c   Takayanagi, Ryoichi ^d   Sasano, Hironobu ^e   Takeda, Yoshiyu ^f   Shibata, Hirotaka ^g   Sone, Masakatsu ^h   Satoh, Fumitoshi ^e   Yamada, Masanobu ⁱ   Ueshiba, Hajime ^j   Katabami, Takuyuki ^k   Iwasaki, Yasumasa ^l   Tanaka, Hirotoshi ^m   Tanahashi, Yusuke ⁿ   Suzuki, Shigeru ⁿ   Hasegawa, Tomonobu ^o   Katsumata, Noriyuki ^p   Tajima, Toshihiro ^q   Yanase, Toshihiko ^a   more..

^a FUKUOKA UNIVERSITY   (Japan)

^b YOKOHAMA ROSAI HOSPITAL   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

^e TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f KANAZAWA UNIVERSITY   (Japan)

^g OITA UNIVERSITY   (Japan)

^h KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^j TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k ST MARIANNA UNIVERSITY   (Japan)

^l KOCHI UNIVERSITY   (Japan)

^m UNIVERSITY OF TOKYO   (Japan)

ⁿ ASAHIKAWA MEDICAL COLLEGE   (Japan)

^o KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^p NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^q HOKKAIDO UNIVERSITY   (Japan)

more..

Author keywords

Medical treatment; Nationwide epidemiological study; Primary aldosteronism; Prognosis; Surgical treatment

Indexed keywords

ADRENAL HYPERPLASIA; ARTICLE; DIASTOLIC BLOOD PRESSURE; EPIDEMIOLOGICAL DATA; FEMALE; HUMAN; HYPERTENSION; HYPOKALEMIA; JAPAN; MAJOR CLINICAL STUDY; MALE; PRIMARY HYPERALDOSTERONISM; PROGNOSIS; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ADENOMA; ALDOSTERONE; EPIDEMIOLOGIC STUDIES; FEMALE; HEALTH SURVEYS; HUMANS; HYPERALDOSTERONISM; HYPERPLASIA; HYPERTENSION; HYPOKALEMIA; JAPAN; MALE; PROGNOSIS; QUESTIONNAIRES; ZONA GLOMERULOSA;

EID: 84893422145     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ13-0353     Document Type: Article

References (15)

1. Conn JW (1955) Presidential address. Part I. Painting background. Part II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 45: 3-17.
2. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, et al. (2008) Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93: 3266-3281.
3. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, et al. (2005) Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45: 1243-1248.
4. Nishikawa T, Omura M, Satoh F, Shibata H, Takahashi K, et al. (2011) Guidelines for the diagnosis and treatment of primary aldosteronism: the Japan Endocrine Society 2009. Endocr J 58: 711-721.
5. Nishikawa T, Omura M, Saito J, Matsuzawa Y (2012) Primary aldosteronism: comparison between guidelines of the Japanese and the US Endocrine Society. Expert Rev Endocrinol Metab 7: 637-645.
6. Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T (2004) Prospective Study on the Prevalence of Secondary Hypertension among Hypertensive Patients Visiting a General Outpatient Clinic in Japan. Hypertens Res 27: 193-202.
7. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Porteri E, et al. (2006) prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 48: 2293-2300.
8. Gordon RD, Ziesak MD, Tunny TJ, Stowasser M, Klemm SA (1993) Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihy pertensive drug trial volunteers. Clin Exp Pharmacol Physiol 20: 296-298.
9. Miyake Y, Tanaka K, Nishikawa T, Naruse M, Takayanagi R, et al. (2012) The nationwide epidemiological study of primary aldosteronism, adrenal subclinical Cushing's syndrome, Addison's disease (second survey, final report). The annual report of the Ministry of Health and Welfare "Disorder of Adrenal Hormones" Research Committee, Japan 2012 pp23-38.
10. Nishikawa T, Saito J, Omura M (2007) Prevalence of primary aldosteronism: should we screen for primary aldosteronism before treating hypertensive patients with medication? Endocr J 54: 487-495.
11. Armanini D, Scaroni C, Mattarello MJ, Fiore C, Albiger N, et al. (2005) Idiopathic primary hyperaldosteronism: normalization of plasma aldosterone after one month withdrawal of long-term therapy with aldosterone-receptor antagonist potassium canrenoate. J Endocrinol Invest 28: 236-240.
12. Armanini D, Fiore C, Pellati D (2007) Spontaneous resolution of idiopathic aldosteronism after long-term treatment with potassium canrenoate. Hypertension 50: e69-e70.
13. Lucatello B, Benso A, Tabaro I, Capello E, Caprino MP, et al. (2013) Long-term re-evaluation of primary aldosteronism after medical treatment reveals high proportion of normal mineralocorticoid secretion. Eur J Endocrinol 168: 525-532.
14. Yoneda T, Demura M, Takata H, Kometani M, Karashima S, et al. (2012) Unilateral primary aldosteronism with spontaneous remission after long-term spironolactone therapy. J Clin Endocrinol Metab 97: 1109-1113.
15. Karagiannis A, Tziomalos K, Papageorgiou A, Kakafika AI, Pagourelias ED, et al. (2008) Spironolactone versus eplerenone for the treatment of idiopathic hyperaldos teronism. Expert Opin Pharmacother 9: 509-515.